In September 2024, we showcased our phase 1 dose escalation study for EBC-129 (NCT05701527) at European Society for Medical Oncology (ESMO) Congress. Further to the ESMO poster presentation, we are happy to announce that we have completed enrolment of the pancreatic ductal adenocarcinoma (PDAC) cohort in the ongoing dose expansion part of EBC-129’s Phase […]
EDDC is excited to share that we will be collaborating with Partex, a leading provider of AI-driven solutions in the pharmaceutical industry, to bring forward an innovative approach for early drug discovery and development. In this partnership, Partex will initially use its “Asset Exchange” technology platform to identify novel indications for EDDC’s portfolio assets. The parties
EBC-129 is the first made-in-Singapore antibody-drug conjugate (ADC) to enter clinical development. It selectively targets cancer cells across a range of solid tumours. The Phase 1 trial for EBC-129 began with a dose escalation study in May 2023. The trial has entered into dose expansion as of 13 May 2024. With the initial safety and
EDDC is proud to share that we are embarking on a partnership with ImmunoScape to develop novel T cell receptor-based therapeutics! Under the terms of the agreement, ImmunoScape will contribute their repertoire of highly potent tumor-specific TCR candidates to EDDC’s expertise in therapeutic protein design and antibody engineering, to jointly develop innovative off-the-shelf TCR-based bispecific
XtalPi and EDDC embarks on a new collaboration with the signing of this MoU. This agreement builds and expands from an ongoing collaboration that utilizes AI and automation to accelerate the drug discovery program for non-small cell lung cancer (NSCLC). With XtalPi’s automation resources and AI capabilities complimenting EDDC’s industry know-how in drug discovery and
EARO turns 3 this year! To mark this occasion, we are excited to share the EARO Review (2020-2022)! EDDC launched EARO (the EDDC Academic Research Organisation) as a service initiative in mid-2020. The goal was to enable early-stage drug discovery in Singapore by creating multiple pathways for the local academic and biotech community to access
EARO Review (2020 – 2022) – A Review of EARO’s first 3 years Read More »
EDDC has signed a MoU with BioCurate to bring together complementary scientific and business development expertise and explore opportunities for co-development on projects with the potential to enter the market as new commercially viable therapies.
BioCurate and EDDC Signs MoU To Announce Strategic Alliance Read More »
The Experimental Drug Development Centre (EDDC), Singapore’s national platform for drug discovery and development, is pleased to share that a first patient has been dosed at the National Cancer Centre Singapore (NCCS) in the first-in-human trial of EBC-129.
EDDC signed a 5-year MOU with CRH to explore collaborations that leverage the complementary capabilities, platforms and technologies from both partners to accelerate oncology pipeline assets across a range of developmental stages & modalities. Click here to read about it in detail.
Cancer Research Horizons and EDDC announce 5-year alliance Read More »
Approval has been obtained from the U.S. Food and Drug Administration (FDA) to conduct the first-in-human trial for EBC-129 in patients with solid tumours EBC-129 is the first made-in-Singapore antibody-drug conjugate (ADC) that is entering clinical development. It is able to selectively target cancer cells across a range of solid tumours. The ADC and the
First Made-in-Singapore Antibody-Drug Conjugate (ADC) Approved to Enter Clinical Trials Read More »
